Skip to main content
Clinical Trials/NCT01097551
NCT01097551
Completed
Not Applicable

Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes

Assistance Publique - Hôpitaux de Paris1 site in 1 country38 target enrollmentJanuary 2011

Overview

Phase
Not Applicable
Intervention
Trinitrin
Conditions
Type 1 Diabetes Mellitus
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
38
Locations
1
Primary Endpoint
Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit)
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The aim of the study is to progress in the understanding of the early retinal vascular and neural abnormalities in patients with diabetes, using a new device, the Dynamic Vessel Analyzer. The Dynamic Vessel Analyzer allows to measure the diameter of the retinal vessels and to assess how it varies in presence of various stimuli. Then, we will be able to assess if a vascular and/or a neural dysfunction is present early in patient with diabetes.

Detailed Description

Twenty patients with type 1 diabetes without diabetic retinopathy and without arterial hypertension will be compared with 20 sex and aged-matched healthy control subjects. To assess the presence of retinal endothelial dysfunction, the variations of the diameters of the retinal vessels will be assessed using the Dynamic Vessel Analyzer, before and after flicker light stimulation, sublingual nitroglycerin, neosynephrine eyedrops, and isometric contraction. To assess the presence of peripheral endothelial dysfunction, the microcirculation of the forearm skin will be studied using iontophoresis with acetylcholine delivery, and heat delivery, both coupled with blood flow measurement using laser Doppler. An intravital capillaroscopy of the phalanx skin will be performed. The serum levels of CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin will also be measured.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
July 2011
Last Updated
13 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • For diabetic patients :
  • age between 20 and 60
  • type 1 diabetes mellitus
  • diabetes duration of more than 5 years
  • no diabetic retinopathy on fundus examination or fundus photographs
  • no systemic hypertension (defined as systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg)
  • For control subjects :
  • sex and age matching with the diabetic patients
  • no diabetes, no familial or personal history of elevated blood sugar
  • Non-diabetic subjects, criteria defined by a fasting glucose \<1.10 g / l and an HbA1c \<6.5% (according to Lariboisière biochemistry laboratory HbA1c)

Exclusion Criteria

  • For both diabetic patients and control subjects :
  • presence of cataract or history of cataract surgery
  • intraocular pressure of more than 21 mmHg
  • treatment with vasoactive drugs
  • tobacco consumption of more than 20 cigarettes a day
  • Contraindications to trinitrin administration: hypersensitivity to trinitrin, treatment by sildenafil, heart disease, severe arterial hypotension, bradycardia, intracranial hypertension
  • Clinical Raynaud syndrome
  • Pregnant or breast-feeding subject
  • Subject whose age is \<18 and\> 60 years on the day of inclusion
  • Subject with cardiac disease, severe hypotension (BP \<80/50 mmHg), a resting heart rate below 50 beats / minute

Arms & Interventions

Patients with type 1 diabetes

Diabetes duration \>= 5 years, age \>= 18 and \<= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension

Intervention: Trinitrin

Patients with type 1 diabetes

Diabetes duration \>= 5 years, age \>= 18 and \<= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension

Intervention: Neosynephrine 10% collyrium

Patients with type 1 diabetes

Diabetes duration \>= 5 years, age \>= 18 and \<= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension

Intervention: Iontophoresis with acetylcholine delivery

Patients with type 1 diabetes

Diabetes duration \>= 5 years, age \>= 18 and \<= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension

Intervention: Dynamic Vessel Analyzer

Healthy subjects

Sex and age-matched control healthy subjects

Intervention: Trinitrin

Healthy subjects

Sex and age-matched control healthy subjects

Intervention: Neosynephrine 10% collyrium

Healthy subjects

Sex and age-matched control healthy subjects

Intervention: Iontophoresis with acetylcholine delivery

Healthy subjects

Sex and age-matched control healthy subjects

Intervention: Dynamic Vessel Analyzer

Outcomes

Primary Outcomes

Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit)

Time Frame: up to 4 months

Secondary Outcomes

  • Presence of a peripheral endothelial dysfunction(up to 4 months)
  • Correlation between retinal and peripheral endothelial dysfunction (assessment study visit)(up to 4 months)
  • Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin.(up to 4 months)

Study Sites (1)

Loading locations...

Similar Trials